Multiple-dose, placebo-controlled, phase I study of oral dolasetron

Pharmacotherapy

Volumn 16, Issue 2 I, 1996, Pages 253-260

  Hunt, Thomas L ^a   Cramer, Michael ^b   Christy Bittel, Janna ^b   Shah, Ajit K ^b   Meyerson, Laura J ^b   Benedict, Claude R ^c   Hahne, William F ^b  

^a Pharmaco LSR   (United States)

^b SANOFI   (France)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOLASETRON MESILATE; HYDRODOLASETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FLATULENCE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; VERTIGO;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIEMETICS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; HUMANS; INDOLES; MALE; MIDDLE AGED; QUINOLIZINES; SEROTONIN ANTAGONISTS;

EID: 0029920447     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Coates A, Abraham S, Kaye SB, et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8.
2. Cooper S, Georgiou V. The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nurses. Eur J Cancer 1992;28A(suppl 1):S36-8.
3. Frytak S, Moertel CG. Management of nausea and vomiting in the cancer patient. JAMA 1981,245:393-6.
4. Laszlo J, Lucas VS Jr. Emesis as a critical problem in chemotherapy. N Engl J Med 1981;305:948-9.
5. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991;42.551-68.
6. Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991;41:574-95.
7. Plosker GL, Goa KL. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic Drugs 1991,42:805-24.
8. Lee CR, Plosker GL, McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993;46:925-43.
9. Markham A, Sorkin EM. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993,45:931-52.
10. Clavel M, Soukop M, Greenstreet YLA. Improved control of emesis and quality of life with Ondansetron in breast cancer. Oncology 1993,50.180-5.
11. Beck TM. Efficacy of Ondansetron tablets in the management of chemotherapy-induced emesis, review of clinical trials. Semin Oncol 1992,19(6 suppl 15):20-5.
12. Beck TM, Ciociola AA, Jones SE, et al. Efficacy of oral Ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993;118:407-13.
13. 3 antagonists incorporating a novel bridged pseudopelletierine ring system. Act Chim Ther 1989;16:187-98.
14. 3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol 1992;21:9-13
15. Galvan M, Gittos MW, Fatmi M. Dolasetron mesylate. Drugs Future 1993;18:506-9
16. 3 receptor antagonist [abstr] Br J Pharmacol 1992;107(suppl) 449P.
17. 3 receptors. Drug Dev Res 1993;28:87-93.
18. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics. II. Absorption and disposition following single-dose oral administration to normal male subjects. Biopharm Drug Dispos 1993;14.131-41.
19. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics. I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1992;13:693-701.
20. Hunt TL, Cramer M, Shah A, Stewart W, Hahne WF, Benedict CR. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers J Clin Pharmacol 1995;35 705-12.
21. Dixon RM, Cramer M, Conway DW, et al. Single-dose, placebo-controlled, phase I study of oral dolasetron. Pharmacotherapy 1996,16:245-252.
22. Finn AL. Toxicity and side effects of Ondansetron. Semin Oncol 1992,19(4 suppl 10).53-60.
23. Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose ranging phase 1 study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989,7:1137-41.
24. Bryson JC. Clinical safety of Ondansetron. Semin Oncol 1992,19(6 suppl 15):26-32
25. Cooke CE, Mehra IV. Oral Ondansetron for preventing nausea and vomiting. Am J Hosp Pharm 1994;51:762-71
26. Helmers JHJH. Oral Ondansetron in the prevention of postoperative nausea and vomiting. Eur J Anaesthesiol 1992;9(suppl 6):49-54.
27. Blackwell CP, Harding SM. The clinical pharmacology of Ondansetron Eur J Cancer Clin Oncol 1989;25(suppl 1) S21-4
28. Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI. Colonic transit in man is slowed by Ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990;4:139-44.
29. 3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990;35:477-80
30. Smith IE. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 1990;26(suppl 1).S19-23.
31. Zhou SH, Wong S, Rautaharju PM, Kamik N, Calhoun HP. Should the JT rather than the QT interval be used to detect prolongation of ventricular repolarization? J Electrocardiol 1993;25(suppl):131-6.
32. 3 receptor antagonists, m anesthetized dogs. Drug Dev Res 1991;24:277-84.
33. Baltzer L, Kris MG, Hinkley L, et al. Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): a possible drug class effect without sequelae? [abstr]. Proc Am Soc Clin Oncol 1994,13:433.
34. Lifsey DS, Gralla RJ, Clark RA, Kline RC. Electrocardiographic changes with serotonin antagonist antiemetics: rate of occurrence and clinical relevance [abstr]. Proc Am Soc Clin Oncol 1993;12:463.
35. Addelman M, Erlichman C, Fine S, Wan D, Murray C. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 1990;8:337-41.
36. 2) cisplatin (CDDP) containing chemotherapy [abstr] Proc Am Soc Clin Oncol 1994,13:445.
37. Kasimis B, Tapazoglou E, Schulman P, et al. A double-blind, randomized study of two different dose regimens of intravenous (IV) dolasetron (DOL) in patients (PTS) receiving high dose cisplatin (CDDP) chemotherapy [abstr]. Proc Am Soc Clin Oncol 1994; 13 446.